References

• Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology 1996; 47(6 Suppl 3): S137–S45.
   PubMed Web of Science ®Google Scholar
• Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003; 110(5): 509–15.
   Web of Science ®Google Scholar
• Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004; 25(1–2): 233–42.
   PubMed Web of Science ®Google Scholar
• Sowa BN, Todd KG, Tanay VA, Holt A, Baker GB. Amine oxidase inhibitors and development of neuroprotective drugs. Curr Neuropharmacol 2004; 2(2): 153–68.
   Google Scholar
• Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7(4): 295–309.
   PubMed Web of Science ®Google Scholar
• Al-Nuaimi SK, MacKenzie EM, Baker GB. Monoamine oxidase inhibitors and neuroprotection: A review. Am J Ther 2012; (in press).
   Google Scholar
• Frampton JE, Plosker GL. Selegiline transdermal system in major depressive disorder: profile report. CNS Drugs 2007; 21(6): 521–4.
   Web of Science ®Google Scholar
• Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord 2011; 26(6): 1072–82.
   Web of Science ®Google Scholar
• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004; 11(15): 2033–43.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, El ReFaey H, et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 2006; 7(11): 1513–29.
   PubMed Web of Science ®Google Scholar
• Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003; (1): CD000442.
   Google Scholar
• Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, FitzerAttas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24(4): 564–73.
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010; 92(3): 330–44.
   PubMed Web of Science ®Google Scholar
• Eliash S, Dror V, Cohen S, Rehavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res 2009; 1256:138–48.
   PubMed Web of Science ®Google Scholar
• Tazik S, Johnson S, Lu D, Johnson C, Youdim MB, Stockmeier CA, et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res 2009; 15(3): 284–90.
   Web of Science ®Google Scholar
• Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 2008; 105(5): 1970–8.
   Web of Science ®Google Scholar
• Dimpfel W, Hoffmann JA. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 2011; 11:2.
   PubMedGoogle Scholar
• Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002; 326(2): 105–8.
   PubMed Web of Science ®Google Scholar
• Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000; 57(1): 2–12.
   PubMed Web of Science ®Google Scholar
• Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A 2006; 103(10): 3887–9.
   Web of Science ®Google Scholar
• Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 2003; 110(5): 509–15.
   Web of Science ®Google Scholar
• Bar-Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004; 355(3): 169–72.
   Web of Science ®Google Scholar
• Weinstock M, Luques L, Bejar C, Shoham S. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J Neural Transm Suppl 2006; 70:443–6.
   Google Scholar
• Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J 2006; 20(12): 2177–9.
   PubMed Web of Science ®Google Scholar
• Egan CG. Differentiation of hippocampal stem cells into functional neurons: evolving our understanding of monoamine oxidase-A inhibition. Br J Pharmacol 2006; 148(5): 563–4.
   Web of Science ®Google Scholar
• Verleye M, Steinschneider R, Bernard FX, Gillardin JM. Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes. Brain Res 2007; 1138:30–8.
   Web of Science ®Google Scholar
• Malorni W, Giammarioli AM, Matarrese P, Pietrangeli P, Agostinelli E, Ciaccio A, et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 1998; 426(1): 155–9.
   Web of Science ®Google Scholar
• Marangos WF, Young KL, Altman CS, Pocernich, CB, Drake, J, Butterfield DA, et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem Res 2004; 29(4): 741–6.
   Web of Science ®Google Scholar
• Berry MD, Boulton AA. Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicol Teratol 2002; 24(5): 667–73.
   Web of Science ®Google Scholar
• Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16(7): 2365–72.
   PubMed Web of Science ®Google Scholar
• Baker GB, Wong JT, Yeung JM, Coutts RT. Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA). J Affect Disord 1991; 21(3): 207–11.
   Web of Science ®Google Scholar
• Popov N, Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem 1969; 16(3): 899–907.
   Google Scholar
• Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex- -a possible mechanism of neuroprotection in major depression? Neuroscience 2000; 100(4): 681–4.
   PubMed Web of Science ®Google Scholar
• Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker GB. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res 2006; 1122(1): 184–90.
   Web of Science ®Google Scholar
• Song MS, Baker GB, Dursun SM, Todd KG. The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem 2010; 114(5): 1405–13.
   Web of Science ®Google Scholar
• Musgrave T, Benson C, Wong G, Browne I, Tenorio G, Rauw G, et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun 2011; 25(8): 1677–88.
   PubMed Web of Science ®Google Scholar
• MacKenzie EM, Song MS, Dursun SM, Tomlinson S, Todd KG, Baker GB. Phenelzine: An old drug that may hold clues to the development of new neuroprotective agents. Klinik Psikofrmakoloji Bülteni-Bull Clin Psychopharmacol 2010; 20(2): 179–86.
   Web of Science ®Google Scholar
• Yu PH, Wright S, Fan EH, Lun ZR, Gubisne-Harberle D. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta 2003; 1647(1–2): 193–9.
   PubMed Web of Science ®Google Scholar
• Chen K, Maley J, Yu PH. Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem 2006; 99(5): 1413–24.
   PubMed Web of Science ®Google Scholar
• Jiang ZJ, Richardson JS, Yu PH. The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathol Appl Neurobiol 2008; 34(2): 194–204.
   Web of Science ®Google Scholar
• Holt A, Berry MD, Boulton AA. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology 2004; 25(1–2): 251–66.
   Web of Science ®Google Scholar
• Wang EY, Gao H, Salter-Cid L, Zhang J, Huang L, Podar EM, et al. Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem 2006; 49(7): 2166–73.
   Web of Science ®Google Scholar